Please Wait
Applying Filters...
menu
    • menu
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    dksh-m-2025-05-26

    Virtual Booth

    Contact Supplier

    dmfs-not-supported-m-2025-05-19

    Virtual Booth

    An Enquiry

    TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

    Virtual Booth

    Contact Supplier

    LEBSA- Your strategic API source for niche molecules.

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-04-28

    Virtual Booth

    An Enquiry

    Menu

    Evenamide

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Newron's Evenamide Approved for Phase III ENIGMA-TRS Program
    Newron's Evenamide Approved for Phase III ENIGMA-TRS Program

    12 May 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250512167812/en/Newron-Announces-Approval-for-Pivotal-Phase-III-ENIGMA-TRS-Program-With-Evenamide-as-Add-on-Therapy-in-Patients-With-Treatment-resistant-Schizophrenia-TRS

    BUSINESSWIRE
    12 May 2025
    Share Share
    Newron & Myung In Pharm Announce Agreement for evenamide in Korea
    Newron & Myung In Pharm Announce Agreement for evenamide in Korea

    09 Jan 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250109233767/en

    BUSINESSWIRE
    09 Jan 2025
    Share Share
    Newron presents H1 2024 results and provides business update
    Newron presents H1 2024 results and provides business update

    19 Sep 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240919982611/en

    BUSINESSWIRE
    19 Sep 2024
    Share Share
    Newron schizophrenia add-on improves positive, negative symptoms
    Newron schizophrenia add-on improves positive, negative symptoms

    30 Apr 2024

    // Annalee Armstrong FIERCE BIOTECH

    https://www.fiercebiotech.com/ai-and-machine-learning/newrons-schizophrenia-add-improves-symptoms-charging-case-phase-3-test

    Annalee Armstrong FIERCE BIOTECH
    30 Apr 2024
    Share Share
    Data from Newron’s Study and An Evenamide Clinical Outlook Presented at The SIRS
    Data from Newron’s Study and An Evenamide Clinical Outlook Presented at The SIRS

    08 Apr 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240408718700/en

    BUSINESSWIRE
    08 Apr 2024
    Share Share
    Newron Reports Exceptional One-year Results of Study 014/15 With Evenamide
    Newron Reports Exceptional One-year Results of Study 014/15 With Evenamide

    04 Jan 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240104787993/en

    BUSINESSWIRE
    04 Jan 2024
    Share Share